Key facts
- This page summarizes Adam King's Form 4 filing for QSAM Biosciences, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 May 2024, 10:32.
Adam King - 02 May 2024 Form 4 Insider Report for QSAM Biosciences, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 02 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 May 2024, 10:32:04 UTC
- Prior SEC filing
- 29 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam King
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Adam King filed Form 4 for QSAM Biosciences, Inc. on 02 May 2024.
Change
- Previous filing in this sequence was filed on 29 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QSAM
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -11
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Adam King is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of February 7, 2024, by and among QSAM Biosciences, Inc., a Delaware corporation ("Issuer"), Telix Pharmaceuticals Limited, a public limited company registered under the laws of the Commonwealth of Australia ("Telix"), Cyclone Merger Sub I, Inc. ("Merger Sub I"), a Delaware corporation and a direct, wholly owned subsidiary of Telix, Cyclone Merger Sub II, Inc., a Delaware corporation and a direct wholly owned subsidiary of Telix, and David H. Clarke, as stockholder representative to the QSAM stockholders (the "QSAM Stockholder Representative"), effective May 2, 2024 (the "Effective Time"), Merger Sub I merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Telix.
Footnote F2
Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 1,744 fully paid and non-assessable ordinary shares of Telix, and (ii) 2,000 non-transferable contingent value rights representing the right to receive one or more contingent payments, if any, upon the achievement of certain milestones, as set forth in the Contingent Value Rights Agreement by and among QSAM, Telix, the QSAM Stockholder Representative, and Equiniti Trust Company, LLC, as the rights agent.
Footnote F3
At the Effective Time, the closing price of Telix ordinary shares was US$9.62 per share.
Footnote F4
Accounts for a 1-for-2,000 reverse stock-split effective May 2, 2024.